William Aronson, MD

Dr. William Aronson's laboratory and clinical research focuses on translational research in nutrition and prostate cancer. His work focuses on quantity of dietary fat, omega-3 fatty acids from fish oil, caloric restriction, green tea and lycopene. He conducts basic science and clinical research studying the role of these nutritional components for the prevention and treatment of prostate cancer. His present clinical research trials are evaluating a low-fat fish oil diet, a weight loss intervention and green and black tea formulations in men with prostate cancer. This research evaluates both the potential efficacy of these dietary interventions for prostate cancer prevention and treatment and potential serum and tissue biomarkers for a future large-scale nutrition trial in men with prostate cancer.

Aronson also has an extensive clinical research program focusing on multiple important aspects in prostate cancer, including prostate cancer prevention and treatment for early and late stage disease. At present he is conducting a trial evaluating dutasteride for prostate cancer prevention and docetaxel for high risk prostate cancer patients following radical prostatectomy. His clinical research also focuses on predictors of prostate cancer progression in early and late stage prostate cancer. He has also published extensively on obesity and prostate cancer and on the aggressive nature of prostate cancer in African American Men.

Aronson is funded by the National Institutes of Health and the Veterans Administration.

Konijeti R, Koyama S, Gray A, Barnard RJ, Said JW, Castor B, Elashoff D, Wan J, Beltran PJ, Calzone FJ, Cohen P, Galet C, Aronson WJ. Effect of a low-fat diet combined with IGF-1 receptor blockade on 22Rv1 prostate cancer xenografts. Mol Cancer Ther. 2012 Jul;11(7):1539-46. Epub 2012 May 4

Aronson WJ, Kobayashi N, Barnard RJ, Henning S, Huang M, Jardack PM, Liu B, Gray A, Wan J, Konijeti R, Freedland SJ, Castor B, Heber D, Elashoff D, Said J, Cohen P, Galet C. Phase II prospective randomized trial of a low-fat diet with fish oil supplementation in men undergoing radical prostatectomy. Cancer Prev Res (Phila). 2011 Dec;4(12):2062-71. Epub 2011 Oct 25

Gray A, Aronson WJ, Barnard RJ, Mehta HH, Wan J, Said J, Cohen P, Galet C, Aronson WJ, Mehta H. Global Igfbp1 deletion does not affect prostate cancer development in a c-Myc transgenic mouse model. J Endocrinol. 2011 Dec;211(3):297-304. Epub 2011 Sep 8

Konijeti R, Henning S, Moro A, Sheikh A, Elashoff D, Shapiro A, Ku M, Said JW, Heber D, Cohen P, Aronson WJ. Chemoprevention of prostate cancer with lycopene in the TRAMP model. Prostate. 2010 Oct 1;70(14):1547-54.

Kobayashi N, Barnard RJ, Henning SM, Elashoff D, Reddy ST, Cohen P, Leung P, Hong-Gonzalez J, Freedland SJ, Said J, Gui D, Seeram NP, Popoviciu LM, Bagga D, Heber D, Glaspy JA, Aronson WJ. Effect of altering dietary omega-6/omega-3 fatty acid ratios on prostate cancer membrane composition, cyclooxygenase-2, and prostaglandin E2. Clin Cancer Res. 2006; 12(15): 4662-70.